Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia.

ABSTRACT: The combination of Venetoclax (VEN), a BCL2 inhibitor, and Azacitidine (AZA), a hypomethylating agent, is the standard treatment for acute myelogenous leukemia (AML) in patients older than 65 years who are not eligible for intensive chemotherapy. While high response rates for this treatment have been noted, it has been also reported that the anti-apoptotic BCL2 family proteins BCL-XL and MCL1 may be involved in VEN resistance. However, no study has heretofore been conducted to investigate the effectiveness of treatment and the expression of BCL-XL or MCL1 in patients treated with VEN + AZA therapy. In this study, we analyzed blasts from patients with newly diagnosed AML treated with VEN + AZA therapy by qPCR, confirmed by siRNA in cultured cell lines, and evaluated the validity of the immu

SUBMITTER: Kamihara Y 

PROVIDER: S-EPMC12857986 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature